This post has been updated to fix the spelling of Novavax's name.
Vaccine maker Novavax has announced that it has begun a phase III trial of its SARS-CoV-2 vaccine in the UK and plans to begin a US trial next month, the New York Times reports.
This post has been updated to fix the spelling of Novavax's name.
Vaccine maker Novavax has announced that it has begun a phase III trial of its SARS-CoV-2 vaccine in the UK and plans to begin a US trial next month, the New York Times reports.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.